warnings and cautions
5 WARNINGS AND PRECAUTIONS Can worsen cardiac function. ( 5.1 ) 5.1 Worsening Cardiac Function Use in patients with impaired cardiac response may worsen cardiac output.
Vasostrict
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Vasostrict
- Generic name
- VASOPRESSIN
- Manufacturer
- Medical Purchasin Solutions, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 6672a5c9-bcfd-d7fc-e053-2991aa0aef88
- SPL ID
- fd1a231f-3406-51ef-e053-6394a90abf4e
- Version
- 3
- Effective date
- 2023-06-01
- Source export date
- 2026-09-28
- Source partition
- 1
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/9c7783846d422acb0c9e59457606951c785a7d28cc631c8cc4839d0dc7c55f39/drug-label-0001-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:14:10
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 204485 | derived:openfda.application_number |
| application number | NDA204485 | openfda.application_number | |
| brand name | Vasostrict | openfda.brand_name | |
| generic name | VASOPRESSIN | openfda.generic_name | |
| manufacturer name | Medical Purchasin Solutions, LLC | openfda.manufacturer_name | |
| ndc | package | 71872-7014-1 | openfda.package_ndc |
| ndc | product | 71872-7014 | openfda.product_ndc |
| ndc11 | package | 71872701401 | derived:openfda.package_ndc |
| rxcui | 313578 | openfda.rxcui | |
| rxcui | 1593738 | openfda.rxcui | |
| spl id | fd1a231f-3406-51ef-e053-6394a90abf4e | id | |
| spl set id | 6672a5c9-bcfd-d7fc-e053-2991aa0aef88 | set_id | |
| unii | Y87Y826H08 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia Gastrointestinal disorders: Mesenteric ischemia Hepatobiliary: Increased bilirubin levels Renal/urinary disorders: Acute renal insufficiency Vascular disorders: Distal limb ischemia Metabolic: Hyponatremia Skin: Ischemic lesions The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.